Current Medical Research and Opinion最新文献

{"title":"A novel hypothesis for stroke prediction, introducing CHA₂DS₂-VAScF.","authors":"Ahmed B Shamsulddin","doi":"10.1080/03007995.2026.2692164","DOIUrl":"10.1080/03007995.2026.2692164","url":null,"abstract":"<p><p>Preventing strokes in patients with atrial fibrillation (AF) is one of the most critical daily tasks facing clinicians in cardiovascular medicine. Yet, our primary tool-the CHA₂DS₂-VASc score-frequently misses the mark because it completely ignores heritable risk. While we have landmark evidence showing that a family history of stroke is a powerful, independent risk factor, we still lack a practical way to use this information in daily practice. This gap between evidence and daily practice leaves vulnerable patients unprotected. In this commentary, we hypothesize: the CHA₂DS₂-VAScF score, which adds a single point for a positive family history of thrombotic events (ischemic stroke, heart attack, or blood clots). By translating established genetic risk into a practical bedside tool, CHA₂DS₂-VAScF can help us identify high-risk patients who currently slip through the cracks-especially those with \"borderline\" scores who might otherwise be denied life-saving therapy.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"873-877"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seizing the opportune moment: early use of antiplatelet therapy for thrombolysis.","authors":"Yifan Ma, Song Kang","doi":"10.1080/03007995.2026.2692796","DOIUrl":"10.1080/03007995.2026.2692796","url":null,"abstract":"<p><p>Intravenous thrombolysis remains a cornerstone intervention for restoring cerebral perfusion in patients with acute ischemic stroke (AIS), with recombinant tissue plasminogen activator (rt-PA) being the most widely employed agent globally. Post-thrombolytic complications, including hemorrhagic transformation, vascular reocclusion, cerebral edema, seizures, and allergic reactions, pose significant clinical challenges. Among these, hemorrhagic transformation is a primary concern during early revascularization, particularly in patients treated within the therapeutic time window. Despite its clinical importance, the optimal timing for initiating antiplatelet therapy after ischemic stroke remains unresolved, and considerable controversy persists in practice. This narrative review critically examines current clinical evidence and underlying pathophysiological mechanisms related to early antiplatelet therapy following intravenous thrombolysis. We focus on a key clinical challenge: the safety and efficacy of initiating antiplatelet treatment in the early post-thrombolysis period, particularly among patients experiencing early neurological deterioration or at elevated risk for specific hemorrhagic transformation subtypes, such as hemorrhagic infarction (HI). By comparing early antiplatelet strategies with the conventional 24-hour delayed initiation protocol, this review integrates findings from pivotal clinical trials and mechanistic studies to elucidate the balance between the risk of symptomatic intracranial hemorrhage (sICH) and the potential for achieving functional independence at three months.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1075-1091"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148337936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidrug-resistant <i>Pseudomonas aeruginosa</i> in Jordan: epidemiology, trends, determinants, and clinical outcomes.","authors":"Ahmad Z Al Meslamani, Dania Abu-Naser, Anan S Jarab, Khadeijah Ahmed Al Marshoodi","doi":"10.1080/03007995.2026.2696049","DOIUrl":"10.1080/03007995.2026.2696049","url":null,"abstract":"<p><strong>Background: </strong>Multidrug-resistant <i>Pseudomonas aeruginosa</i> (MDR-PA) is a major cause of healthcare-associated infections, yet contemporary multicentre data from Jordan are limited.</p><p><strong>Aims: </strong>To describe the prevalence, temporal trends, determinants, and in-hospital outcomes of MDR-PA across Jordanian hospitals over an 11-year period, and to define implications for national surveillance, infection prevention, and antimicrobial stewardship.</p><p><strong>Methods: </strong>This is a retrospective observational study using the Hakim electronic database and included the first <i>P. aeruginosa</i> isolates per patient from 21 hospitals between 2013 and 2023. MDR-PA was defined as non-susceptibility to ≥3 antipseudomonal classes. Logistic regression was used to identify determinants associated with MDR-PA and in-hospital mortality.</p><p><strong>Results: </strong>Among 4,714 patients, 610 (12.9%) had MDR-PA. Patients with MDR-PA were older and more often nosocomial, with longer median hospital stay than non-MDR-PA. The proportion of MDR-PA increased significantly over time; each calendar year was associated with a 21% higher odds of MDR [adjusted odds ratio (OR) 1.21, 95% CI 1.14-1.28]. Nosocomial acquisition nearly doubled the odds of MDR-PA (aOR 1.91, 95% CI 1.48-2.45). Overall, in-hospital mortality was 17.6% and higher in MDR-PA in crude analyses, but MDR status was not independently associated with mortality after full adjustment. Mortality was driven by older age, ICU admission, community acquisition, and longer stay.</p><p><strong>Conclusion: </strong>MDR-PA prevalence and temporal trends in Jordan are alarming. The absence of an independent mortality association should be interpreted cautiously because residual confounding by comorbidity, illness severity, prior antimicrobial exposure, and treatment appropriateness could not be fully addressed.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"987-999"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148374728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.","authors":"Naresh Bumma, Hans C Lee, Joshua Richter, James E Hoffman, Jeffrey A Zonder, Mirko Fillbrunn, Viviana Garcia-Horton, Zheng-Yi Zhou, Yingxin Xu, Heather Burnett, James Harnett, Timothy J Inocencio, Michelle Little, Katherine Knorr, Glenn S Kroog, Wanning Xu, Qiufei Ma, Sundar Jagannath","doi":"10.1080/03007995.2026.2686032","DOIUrl":"10.1080/03007995.2026.2686032","url":null,"abstract":"<p><strong>Objective: </strong>Assessing the comparative efficacy of novel chimeric antigen receptor T-cell (CAR-T) and bispecific antibody (bsAb) therapies for relapsed/refractory multiple myeloma (RRMM) is crucial for informed treatment decisions. This study systematically reviewed indirect treatment comparisons (ITCs) evaluating the efficacy of approved CAR-T therapies and bsAbs in triple-class exposed RRMM.</p><p><strong>Methods: </strong>Systematic searches identified ITCs comparing the efficacy of approved BCMA- and GPRC5D-targeted therapies: elranatamab, linvoseltamab, talquetamab, teclistamab, ciltacabtagene autoleucel (cilta-cel), and idecabtagene vicleucel (ide-cel). Screening used large language models and human researchers, with full-text review and data extraction performed by two researchers. Results were synthesized qualitatively.</p><p><strong>Results: </strong>Eleven matching-adjusted indirect comparisons (MAICs) were included; six compared bsAbs, four compared bsAbs and CAR-Ts, and one compared CAR-Ts. All MAICs were adjusted for differences in refractory status, cytogenetic risk, disease stage, and presence of extramedullary disease. Across all MAICs identified, elranatamab showed significant improvements versus teclistamab (ORR, DOR, PFS, OS); linvoseltamab showed significant improvements versus elranatamab (ORR, ≥CR), talquetamab (≥CR, DOR), teclistamab (DOR, PFS, OS), ide-cel (≥CR, DOR, PFS), and cilta-cel (DOR); ide-cel showed significant improvements versus teclistamab (OS) and elranatamab (OS); and cilta-cel showed significant improvements versus linvoseltamab (ORR, ≥VGPR, ≥CR), and ide-cel (ORR, ≥CR, DOR, PFS, OS).</p><p><strong>Conclusion: </strong>Although head-to-head trials are not available, the MAICs provide hypothesis-generating estimates of the relative efficacy of approved bsAbs and CAR-Ts for triple-class exposed RRMM. Based on the available evidence, linvoseltamab and cilta-cel were frequently associated with improved efficacy across a range of comparators and endpoints; however, these findings included both statistically significant and numerically favorable results and should be interpreted cautiously in light of cross-study heterogeneity and the limitations associated with unanchored MAICs.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"971-985"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148315977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of sodium-glucose cotransporter 2 inhibitors on body weight and metabolic parameters in obese patients with and without type 2 diabetes: a systematized narrative review.","authors":"Djordje Baletic, Natasa Bozic, Milica Paut Kusturica, Ljiljana Tomic, Violeta Ilic Todorovic, Sara Vasovic, Aleksandar Raskovic","doi":"10.1080/03007995.2026.2690834","DOIUrl":"10.1080/03007995.2026.2690834","url":null,"abstract":"<p><p>Obesity is a chronic disorder resulting from a prolonged energy imbalance, with a significant contribution of genetic, metabolic, and lifestyle factors, and is recognized as one of the leading global public health challenges. It is associated with the development of numerous chronic non-communicable diseases, including type 2 diabetes mellitus and cardiovascular diseases. Chronic low-grade inflammation represents a key pathophysiological link between obesity and its comorbidities, and SGLT2 inhibitors have been shown to exert anti-inflammatory effects, providing a biological rationale for investigating their therapeutic potential in obesity management. SGLT2 inhibitors reduce glycemia <i>via</i> an insulin-independent mechanism and contribute to body weight loss through increased glucosuria. Although their beneficial metabolic effects are well documented in patients with T2DM, evidence regarding their efficacy in reducing body weight in patients without T2DM remains limited, and their therapeutic positioning relative to GLP-1 receptor agonists has not been comprehensively evaluated. This systematized narrative review aims to address this gap by synthesizing available preclinical and clinical evidence on the effects of SGLT2 inhibitors on body weight and metabolic parameters in obese patients with and without T2DM. Preclinical studies demonstrate reductions in visceral adipose tissue, increased fatty acid oxidation, and activation of the browning of white adipose tissue. Clinical trials confirm modest but consistent reductions in body weight, generally ranging from 2 to 4 kg, in obese patients with and without T2DM, along with improvements in glycemic control and metabolic parameters. The long-term effectiveness of SGLT2 inhibitors in body weight management is limited by compensatory hyperphagia and plateau effects. Current evidence is insufficient to support their routine use as primary anti-obesity agents. Compared to GLP-1 receptor agonists and dual incretin therapies, the magnitude of weight loss achieved with SGLT2 inhibitors remains substantially lower. Therefore, SGLT2 inhibitors are best positioned as adjunctive components of a comprehensive metabolic therapeutic strategy.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1001-1018"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The importance of patient life engagement as a treatment goal in adults living with schizophrenia: a plain language summary.","authors":"Zahinoor Ismail, Stine Rasmussen Meehan, Anja Farovik, Shivani Kapadia, Anton M Palma, Stephane Alexandre Regnier, Zhen Zhang, T Michelle Brown, Mirline Milien, Roger S McIntyre","doi":"10.1080/03007995.2026.2687467","DOIUrl":"10.1080/03007995.2026.2687467","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1019-1030"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148327276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enabling remuneration for patient authors of company-sponsored publications: approaches and case study examples aligned with Good Publication practice.","authors":"Trishna Bharadia, Adeline Rosenberg, Mithi Ahmed-Richards, Lisa M DeTora, Sally-Anne Dews, Stephanie Dooley, Laura Dormer, Louise Roch, Simon R Stones, Dikran Toroser","doi":"10.1080/03007995.2026.2692129","DOIUrl":"10.1080/03007995.2026.2692129","url":null,"abstract":"<p><p>Patient authors have been increasingly included on company-sponsored research publications, contributing a unique and needed expertise. Patients are routinely and rightfully remunerated for their contributions to advisory boards and non-authorship publication activities, such as peer review. However, the remuneration of patients for authorship activities has remained inconsistent and even contentious. Here, a working group of Good Publication Practice (GPP) steering committee members, patients and patient involvement and engagement experts, and industry partners present six commonly described barriers to and arguments against patient author remuneration. The working group provides practical solutions and counterarguments to enable industry sponsors to equitably, fairly, and transparently remunerate patient authors. The barriers include (1) general resistance to or unawareness of patient authorship; (2) conflict of interest and compliance risks; (3) operational and logistical challenges; (4) concerns about equity, fairness, and scalability; (5) external perceptions within scholarly publishing; and (6) lack of clarity regarding alternative methods of recognition. Solutions to these barriers are supported by a case study from industry to share real-world implementation recommendations. These recommendations provide an action plan for the development and utilization of a framework to enable patient author remuneration, based on one company's experience. In short, the principles and guidance that underpin fair remuneration in other patient engagement activities can and should be extended to authorship, ensuring appropriate recognition of the value that patient authors bring, rather than risking the absence of patient authors altogether.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1053-1063"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication adherence measurement methods and their reported relationship with medication safety outcomes: a scoping review.","authors":"Nouf Aloudah","doi":"10.1080/03007995.2026.2687682","DOIUrl":"10.1080/03007995.2026.2687682","url":null,"abstract":"<p><strong>Objective: </strong>To map medication adherence measurement methods used in studies examining medication safety outcomes in adults receiving long-term pharmacotherapy, and to describe how adherence-safety relationships have been studied and reported.</p><p><strong>Methods: </strong>A scoping review was conducted using systematic searches of PubMed, Web of Science, and Scopus from 1 January 2000 to 9 February 2026. Eligible studies were those that explicitly examined the relationship between adherence and at least one medication safety outcome.</p><p><strong>Results: </strong>Of 2395 records identified, 216 full-text reports were assessed and 29 studies were included. Most studies showed a pattern of higher safety burden with poorer adherence (<i>n</i> = 18, 62.1%), while lower safety burden with better adherence (<i>n</i> = 4, 13.8%), mixed patterns (<i>n</i> = 3, 10.3%), no clear association (<i>n</i> = 3, 10.3%), and indirect safety-related nonadherence evidence (<i>n</i> = 1, 3.4%) were also identified. Analytical direction varied: 15 studies examined safety-to-adherence pathways, where medication safety burden or safety-related factors were treated as the exposure or predictor of adherence, non-adherence, or discontinuation; six examined adherence-to-safety pathways, where adherence, non-adherence, persistence, or adherence trajectory was treated as the exposure or predictor of subsequent medication safety outcomes; five were cross-sectional/descriptive/undirected; and three had complex or indirect analytical structures.</p><p><strong>Conclusion: </strong>This scoping review shows that adherence-safety relationships have been studied across heterogeneous diseases, measurement approaches, safety outcomes, and analytical directions. Most studies examined safety-to-adherence pathways, whereas fewer examined adherence-to-safety pathways, and many designs could not establish temporality. Findings suggest that adherence assessment, medication review, and adverse drug reaction monitoring may be more informative when considered together, particularly in pharmacy practice. Greater standardization of adherence constructs and safety outcome definitions, clearer reporting, longitudinal designs, and explicit conceptual models are needed to strengthen future research.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"899-928"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148367212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D and ER levels of expression and other clinicopathologic characteristics in breast cancers.","authors":"Nicholas Lambert, Jonathan Hammond, Ioannis A Voutsadakis","doi":"10.1080/03007995.2026.2690007","DOIUrl":"10.1080/03007995.2026.2690007","url":null,"abstract":"<p><strong>Background: </strong>Vitamin D is a steroid hormone with many vital physiological functions. There is extensive research suggesting that vitamin D additionally acts as a protective factor against the development and progression of breast cancer. However, there is limited detail regarding the effect of vitamin D insufficiency or deficiency on the clinicopathologic characteristics of breast cancer.</p><p><strong>Methods: </strong>A retrospective analysis of all the breast cancer patients that had received treatment at the Algoma District Cancer Program, Ontario, Canada between 2016 and 2024 was conducted. Patients were grouped according to their circulating 25-hydroxyvitamin D levels as sufficient (25-hydroxyvitamin D- 25-OHD <math><mrow><mo>≥</mo></mrow></math> 75 nmol/L) or insufficient (25-OHD < 75 nmol/L). The groups were compared for demographic and tumor characteristics along with outcomes. An analysis according to 25-OHD deficiency (25-OHD < 50 nmol/L) was also performed.</p><p><strong>Results: </strong>Patients with vitamin D sufficiency represented 55.7% (295 of 530 patients) of the whole cohort, while patients with vitamin D insufficiency represented 44.3% (235 of 530 patients) in the cohort. Patients with vitamin D sufficiency were older, less likely to be obese, and were more likely to have tumors with high estrogen receptor (ER) expression. Vitamin D insufficient patients had shorter overall survival (LogRank test <i>p</i> = .02). The association, however, was lost on the multivariate analysis.</p><p><strong>Conclusions: </strong>Vitamin D sufficiency in breast cancer patients is associated with older age and lower obesity rates, along with favorable tumor prognostic indicators like high ER expression. Maintaining vitamin D sufficiency may improve breast cancer outcomes.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1043-1051"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148276527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to multi-target stool DNA colorectal cancer screening among Medicare patients in Alabama.","authors":"Shrey Gohil, Mohamed Omar, Matthew L Carnes, Jordan J Karlitz, Nathan Usry, Rajab Idriss, Mallik Greene","doi":"10.1080/03007995.2026.2692800","DOIUrl":"10.1080/03007995.2026.2692800","url":null,"abstract":"<p><strong>Objective: </strong>Colorectal cancer (CRC) incidence and mortality in Alabama are higher than national averages. We assessed adherence to multi-target stool DNA (mt-sDNA) testing and factors associated with adherence among Alabama Medicare enrollees.</p><p><strong>Methods: </strong>Traditional Medicare and Medicare Advantage enrollees aged 65-85 from Alabama who were sent mt-sDNA kits (October 2014-November 2024) were evaluated for mt-sDNA test adherence, defined as return of a valid kit, and time to kit return. Logistic regression analysis was performed to identify demographic factors associated with adherence. Kaplan-Meier analyses and a multivariable Cox proportional hazards model were used to evaluate differences in time to kit return.</p><p><strong>Results: </strong>Overall, 167,675 individuals were included and 78.6% were adherent to mt-sDNA testing. In adjusted logistic regression analyses, patients aged 76-85 years (odds ratio [OR] = 1.24, 95% confidence interval [CI] = 1.20-1.28, <i>p</i> < 0.001, reference: age = 65-75 years), those insured by traditional Medicare (OR = 1.57, 95% CI = 1.53-1.62, <i>p</i> < 0.001, reference: Medicare Advantage), and those with prior mt-sDNA testing history (OR = 2.09, 95% CI = 2.02-2.16, <i>p</i> < 0.001, reference: new patients) were more likely to return kits. Faster kit return was found among patients receiving full digital outreach compared with no digital outreach (adjusted hazard ratio [aHR] = 1.26, 95% CI = 1.24-1.29) and those with prior mt-sDNA testing history (aHR = 1.32, 95% CI = 1.30-1.34) (log-rank <i>p</i> < 0.0001).</p><p><strong>Conclusion: </strong>Overall, 78.6% of Alabama Medicare enrollees completed mt-sDNA testing. mt-sDNA adherence rate was higher in all subgroups analyzed compared with national and state averages with all CRC screening modalities combined. Targeted outreach strategies were associated with higher CRC screening completion and may help inform future screening programs.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"941-951"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}